Clinical trials: Hyperhidrosis
Hyperhidrosis
Study of Glycopyrronium in Axillary Hyperhydrosis
The study is a randomized, double-blind, vehicle controlled, parallel group study, designed to assess the efficacy and safety of glycopyrronium topical wipes, once daily, compared to vehicle in subjects with axillary…
- Trial name
- NCT02530281
- Testing
- glycopyrronium Topical Wipes, Vehicle
- Where
- 31 sites in United States, Germany
- Volunteers
- 344 people
- Sponsor
- Journey Medical Corporation
Palmar Hyperhidrosis
A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis
The objective of this study is to assess the efficacy and safety of glycopyrronium cloth, 2.4% when used to treat palmar hyperhidrosis.
- Trial name
- NCT03880266
- Testing
- Glycopyrronium cloth, 2.4%, Vehicle
- Where
- 7 sites in United States
- Volunteers
- 72 people
- Sponsor
- Journey Medical Corporation
Primary Focal Hyperhidrosis of the Hands
BTX-A Treatment for Palmar Hyperhidrosis
Primary focal hyperhidrosis (excessive sweating) is a debilitating condition affecting approximately 3% of the population in the United States.
- Trial name
- NCT01262339
- Testing
- BTX-A
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Wisconsin, Madison
Primary Axillary Hyperhidrosis
A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- NCT03785587
- Testing
- Sofpironium Bromide Gel, 15%
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Botanix Pharmaceuticals
Primary Axillary Hyperhidrosis
A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- NCT03627468
- Testing
- Sofpironium Bromide Gel, 5%, Sofpironium Bromide Gel, 15%
- Where
- 12 sites in United States
- Volunteers
- 300 people
- Sponsor
- Botanix Pharmaceuticals
Axillary Hyperhidrosis
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- CardiganI (NCT03836287)
- Testing
- Sofpironium Bromide Gel, 15%, Vehicle
- Where
- 39 sites in United States
- Volunteers
- 350 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis
A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults
This is a single-center, prospective, open-label, outpatient pilot study evaluating the efficacy and tolerability of oxybutynin gel for axillary hyperhidrosis.
- Trial name
- NCT02633371
- Testing
- Oxybutynin 3% gel
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Axillary Hyperhidrosis
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- CARDIGANII (NCT03948646)
- Testing
- Sofpironium Bromide, 15%, Vehicle
- Where
- 42 sites in United States
- Volunteers
- 351 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis
Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis
This is an open-label, long-term safety study of glycopyrronium topical wipes, enrolling up to 660 subjects with primary axillary hyperhidrosis who participated in either the DRM04-HH04 or DRM04-HH05 studies.
- Trial name
- NCT02553798
- Testing
- Glycopyrronium Topical Wipes
- Where
- 48 sites in United States, Germany
- Volunteers
- 564 people
- Sponsor
- Journey Medical Corporation
Hyperhidrosis, Hyperhidrosis Palmaris et Plantaris
Management of Palmar Hyperhidrosis With Hydrogel-based Iontophoresis
This study will evaluate the use of hydrogel electrode pads (rather than tap water baths) to deliver iontophoresis treatment using a traditional iontophoresis device.
- Trial name
- NCT02854540
- Testing
- Hydrogel electrode-based iontophoresis
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Stanford University
Hyperhidrosis
Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis
The study is a randomized, double-blind, vehicle controlled, parallel group study, designed to assess the efficacy and safety of glycopyrronium topical wipes, once daily, compared to vehicle in subjects with axillary…
- Trial name
- NCT02530294
- Testing
- glycopyrronium Topical Wipes, Vehicle
- Where
- 20 sites in United States
- Volunteers
- 353 people
- Sponsor
- Journey Medical Corporation